Amphastar Pharmaceuticals (AMPH) Reports Earnings Tomorrow: What To Expect
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting earnings tomorrow after market hours. Here’s what to expect.
Amphastar Pharmaceuticals beat analysts’ revenue expectations last quarter, reporting revenues of $191.8 million, flat year on year. It was an exceptional quarter for the company, with a solid beat of analysts’ revenue estimates and a beat of analysts’ EPS estimates.
This quarter, the market is expecting Amphastar Pharmaceuticals’s revenue to be flat year on year, slowing from the 2.9% increase it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Amphastar Pharmaceuticals has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at Amphastar Pharmaceuticals’s peers in the pharmaceuticals segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Eli Lilly delivered year-on-year revenue growth of 42.6%, beating analysts’ expectations by 7.4%, and Bristol-Myers Squibb reported revenues up 1.4%, topping estimates by 4.8%. Eli Lilly traded up 1.7% following the results while Bristol-Myers Squibb was also up 7.6%.
Investors in the pharmaceuticals segment have had fairly steady hands going into earnings, with share prices down 1.1% on average over the last month. Amphastar Pharmaceuticals is up 6% during the same time and is heading into earnings with an average analyst price target of $31.57 (compared to the current share price of $27.76).
P.S. STOP buying the AI stocks everyone's talking about. The real money? It’s in the profitable pick nobody’s watching yet. We’ve identified an AI profit machine that’s flying under Wall Street’s radar—for now. We can’t keep this research public forever—grab your FREE copy before we pull it offline.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
EUR/JPY slips below 184.00 following Tokyo inflation data, German labor, CPI eyed
Argus Upgrades Deckers Outdoor Corporation (DECK) to Buy from Hold



